NASDAQ:AVRO
AVROBIO Inc Stock News
$1.26
+0.0100 (+0.80%)
At Close: May 08, 2024
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential
Global Leukemia Therapeutics Market Forecast and Opportunities to 2025 - ResearchAndMarkets.com
12:00am, Thursday, 11'th Jun 2020
The
Repligen: Management Gambled With 2020 Guidance But Long-Term Growth Story Looks Compelling (NASDAQ:RGEN)
05:04pm, Wednesday, 10'th Jun 2020
Repligen develops and sells bioprocessing technologies and systems involved in the manufacturing of biological drugs. The company operates within a high growth,
Somebody tell Mesoblast we get the message
01:31pm, Wednesday, 03'rd Jun 2020
Mesoblast has now put out at least nine announcements since April 9 covering the same potential treatment for COVID-19.
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
12:00am, Sunday, 24'th May 2020
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
City of Hope Physicians/Scientists Lead Multiple, Innovative COVID-19 Research Projects
12:00am, Thursday, 21'st May 2020
City of Hope’s physician-scientists and basic scientists are using their expertise to attack the deadly coronavirus on multiple research fronts.
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
11:00am, Thursday, 14'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new preclinical data for AVR-RD-03 for Pom
The
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
11:00am, Wednesday, 13'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new clinical data from its investigational
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
12:00am, Wednesday, 13'th May 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
12:00am, Monday, 11'th May 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transform
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2020 Results - Earnings Call Transcript
03:20pm, Saturday, 09'th May 2020
Catalent, Inc. (NYSE:CTLT) Q3 2020 Earnings Conference Call May 5, 2020 08:15 ET Company Participants Paul Surdez - Vice President, Investor Relations John Chim
We're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
12:36pm, Saturday, 09'th May 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Why Earnings Season Could Be Great for AVROBIO (AVRO)
12:42pm, Friday, 08'th May 2020
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
